Hae Mi Choe, PharmD

home / authors / hae-mi-choe-pharmd

Articles

July 11th 2018

5-ASA to Sulfasalazine Drug Switch Program in Patients With Ulcerative Colitis

Jason R. Goldsmith, MD, PhD Akbar K. Waljee, MD Tom George, PharmD Alexandra Brown, BS Hae Mi Choe, PharmD Mohamed Noureldin, MBBS Steven J. Bernstein, MD, MPH Peter D.R. Higgins, MD, PhD

A 5-aminosalicylic acid (5-ASA) drug switch program switching from 5-ASA to sulfasalazine was instituted for insured patients with ulcerative colitis. Unanticipated barriers limited the number of patients who switched, but significant cost savings were still obtained.

January 14th 2010

New Diabetes HEDIS Blood Pressure Quality Measure: Potential for Overtreatment

Hae Mi Choe, PharmD Steven J. Bernstein, MD, MPH Connie J. Standiford, MD Rodney A. Hayward, MD

The new HEDIS diabetes blood pressure measure may promote performance incentives for overtreatment of blood pressure, causing potential harm, especially in the elderly population.

April 2nd 2009

Moving From A to Z: Successful Implementation of a Statin Switch Program by a Large Physician Group

Fangyan Z. Sy, PharmD Hae Mi Choe, PharmD Diane M. Kennedy, BS Connie J. Standiford, MD Dawn M. Parsons, RPh, MBA Keith D. Bruhnsen, MSW James G. Stevenson, PharmD Steven J. Bernstein, MD

This report shows that a successful, cost-effective statin switch program can be implemented by a large physician group via a centralized, collaborative process.

June 1st 2007

Impact of Patient Financial Incentives on Participation and Outcomes in a Statin Pill-splitting Program

Hae Mi Choe, PharmD James G. Stevenson, PharmD Daniel S. Streetman, PharmD Michele Heisler, MD, MPA Connie J. Standiford, MD John D. Piette, PhD

April 1st 2005

Proactive Case Management of High-risk Patients With Type 2 Diabetes Mellitus by a Clinical Pharmacist: A Randomized Controlled Trial

Hae Mi Choe, PharmD Sonya Mitrovich, MD Daniel Dubay, MD Rodney A. Hayward, MD Sarah L. Krein, PhD, RN Sandeep Vijan, MD